Copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2000
In their trial of 4 nicotine replacement therapy (NRT) products, Hajek and colleagues1 concluded that there were no notable differences in general efficacy among the tested nicotine patch, gum, nasal spray, and inhaler. Indeed, the withdrawal scores, urges to smoke indices, and abstinence rates for patients randomized to each of the 4 groups were not statistically different from one another at the 12-week follow-up. What is notable, however, is that among the participants who were not smoking at 12 weeks, a majority continued to use NRT products. Specifically, 53.8% (14/68), 74.2% (23/54), 76.0% (19/64), and 90.0% (27/68) of patch, inhaler, gum, and nasal spray users, respectively, continued to use their prescribed NRT products. Furthermore, post hoc comparisons indicated that the patch group showed significantly less continued NRT use than those participants using the other 3 NRT products.
Gylys J. Continued Dependence on Nicotine Replacement Therapy Should Be Reported and Discussed in Smoking Cessation Trials. Arch Intern Med. 2000;160(13):2061-2067. doi: